Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: emil who wrote (1801)	3/16/1998 9:22:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 4676

Oach, who said that researchers (excluding me :-)) are honest guys! >> The affected studies may have included human tumor xenograft studies for cancer compounds on which Isis and Novartis have collaborated.<< This are animal drug efficiency studies. >> All toxicology, pharmacokinetics, pharmacology, cell biology and mechanism of action data for these drugs are unaffected by this incident. We also have antitumor data for each of these drugs developed independently of Novartis. No safety data have been affected by this incident.<< At least, the preclinical toxicity and safety data (very important) are not effected. Because they reported news night before important cancer conference (this was not from yesterday) there are to possibility: 1. They want to minimize news negative effect by positive from conference (two presentation), or 2. They want public attention on antisense (one individual scientist can manipulate data from his work only if there are no connection and cooperation with other scientists, not very often-research is team work). Will see market reaction. mz